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http://dx.doi.org/10.1016/j.jmii.2012Background: The number of female injection drug users infected with human immunodefi-
ciency virus (HIV) is increasing in Taiwan. Their human papillomavirus (HPV) infection has
not been fully discussed.
Methods: A cross-sectional study was conducted in a prison for women. Both HIV-positive
and HIV-negative women were enrolled voluntarily. All patients answered self-
administered questionnaires, had a Pap smear, and underwent linear array HPV genotype
tests.
Results: A total of 72 female patients infected with HIV and 76 women who were not in-
fected with HIV were enrolled in this cross-sectional study (mean age, 33.4 years). HPV
infection was detected in 63.9% of patients infected with HIV and 47.4% of HIV-negative
counterparts (pZ 0.043). Oncogenic HPV was detected in 41.6% of patients infected with
HIV and 28.9% of their counterparts (pZ 0.10). A mean of 2.41 types of HPV were detected
in HIV-positive women and 1.53 types were detected in the HIV-negative counterparts
(pZ 0.014). HPV 52 was the most commonly encountered oncogenic type. Only 10.2% of
the patients (10.9% of HIV-positive patients) had vaccine-preventable HPV types. Patients
with abnormal cytology (81.3%) tended to have oncogenic types of HPV infection. HIVt of Infectious Diseases, Taoyuan General Hospital, Department of Health, 1492 Chung-Shan Road,
ail.com (S.-H. Cheng).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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HPV in Taiwanese HIV-positive women 283serostatus was the significant factor associated with oncogenic HPV infection (odds
ratioZ 2.583, 95% confidence interval 1.071e6.231, pZ 0.0347).
Conclusion: Drug-using women infected with HIV had significantly higher rates of HPV infec-
tions, justifying the aggressive screening for cervical dysplasia.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Human papillomavirus (HPV) is a widespread sexually
transmitted infection, with at least 60% of sexually active
adults having experienced a genital HPV infection once in
their lifetime.1 Studies have consistently shown that HPV
infections are detected more frequently in human immu-
nodeficiency virus (HIV)-seropositive women than in their
HIV-negative counterparts, with HPV positivity being re-
ported in approximately 58% of a large group of women
infected with HIV as part of the Women’s Interagency HIV
Study that has been ongoing since 1994.2 HPV prevalence
rates varied in different geographic areas.3,4 In addition,
HPV is more likely to be persistent or reactivated in the
setting of HIV infection.5 There is an accelerated risk of
progression to malignancy in women coinfected with HIV
and HPV.6
In Taiwan, the proportion of newly diagnosed HIV-
infected cases attributed to injection drug users surged
drastically from less than 10% in 2003 to more than 70% in
2005. A previous prevalence study showed that the
proportion of HIV infection in male injection drug users in
Taiwan was 0.23% from 1994 to 20037 and 25.6% in 2005.8 At
the end of 2011, there were more than 22,000 reported
patients infected with HIV in Taiwan, one-third (29.85%) of
whom were injection drug users.9 Sharing of injection
equipment and drug paraphernalia was thought to be the
main mode of HIV transmission among injection drug
users.8
An increase in the number of women with HIV was also
noted in Taiwan. The man-to-woman ratio of patients
infected with HIV decreased from 20:1 in 2003 to 7:1 in
2005, and half of these HIV-positive women (54.4%) were
injection drug users.10 A previous study showed that female
injection drug users infected with HIV were of lower
socioeconomic status, had frequent common sexual and
drug partners, and received poor parental support after
several instances of recidivism.11 Among the female injec-
tion drug users infected with HIV in that study, 64% had
never used condoms and 88% had multiple sexual part-
ners.11 At the end of 2005, Taiwan’s government launched
a harm reduction program that included a needle exchange
program and methadone maintenance therapy, and the
outbreak was under control in 2 years.8,9
One study showed that HPV could be detected in 48.4%
of Taiwanese HIV-positive women,12 but their cohort
comprised no injection drug users. Thus, the prevalence of
HPV infection in HIV-positive female injection drug users in
Taiwan is still unknown. The objectives of this study were
to understand the prevalence of HPV infection in female
illicit drug users who are HIV-positive, and to develop a sex-specific approach to the prevention, diagnosis, and treat-
ment of HPV infection in such cases.
Patients and methods
Study population and collection of specimens
Under Taiwan law, all detainees should be tested for the
presence of HIV-I/II antibodies upon admission to the
detention facility, and those infected with HIV are segre-
gated from HIV-negative detainees. The prevalence of HIV
infection among incarcerated women was 8.5% in 2007.13
This study was conducted in a womens’ prison where, of
approximately 1400 inmates, more than 75% of the incar-
cerations were directly or indirectly associated with illicit
drug usage. During the 2008 annual Pap smear screening,
76 women infected with HIV were invited for testing after
complete information about HPV was provided. Simulta-
neously, an approximately equal number of HIV-negative
patients who were age-matched within  3 years were
enrolled consecutively after informedconsentwas obtained.
Self-administered questionnaires, thin-preparation Pap
smear, and HPV genotyping tests were provided for both
groups. CD4þ T-cell counts using flow cytometry (Coulter
Epics XL, Beckman Coulter, CA, USA) were also evaluated for
all HIV-positive patients. The study was reviewed and certi-
fied by the institutional review boards of Taoyuan General
Hospital, Department of Health (IRB No: TYGH97019) and Far
Eastern Memorial Hospital (FEMH No: 96049).
HIV serologic determination
Initial HIV-I/II antibodies testing was performed using
microparticle enzyme immunoassay (HIV 1/2 gO, Abbott
Diagnostic Division, IL, USA). Samples with positive results
were run in duplicate, and the results were confirmed by
Western blot HIV-1 and HIV-2 assays (New LAV Blot-I and II,
Bio-Rad Fugirebio Inc., Tokyo, Japan).
Cervical cytology
Thin preparation Pap smears (ThinPrep, Hologic Inc.,
Marlborough, MA, USA) were prepared and sent to a certi-
fied laboratory where two cytopathology technicians and
two cytopathologists performed a blind evaluation of the
Pap smears. The results were classified according to the
2001 Bethesda System terminology.14 The cervical cells
were preserved in PreservCyt solution (Cytyc Corp., Marl-
borough, Massachusetts, USA) and stored at e70C for DNA
testing.
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Reverse line blot methods (Linear Array HPV genotyping
test, Roche Molecular System, Branchburg, NJ, US) were
applied. In brief, biotinylated primers were used in multi-
plex polymerase chain reactions to define a nucleotide
sequence in the polymorphic L1 region within the HPV
genome. An additional primer pair targeted at the human
b-globin gene was added as the internal control. The
denatured amplicon was hybridized to a linear array strip
with probes detecting 37 genotypes of the HPV genome (13
types of oncogenic HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, and 68; and 24 types of nononcogenic HPV: 6,
11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 66, 67, 69, 70, 71, 72,
73, 81, 82, 83, 84, IS39, and CP2108) and the human b-
globin gene.15 The assay provided 96% of sensitivity and 99%
of specificity.15Statistical analysis
According to the previous study,2e4 HPV prevalence is 50%
among HIV-positive women and 20% among the general
female population. Sample size is estimated to at least 77
individuals to achieve 0.8 of desired power and 0.05 of
significance level. Demographic data are presented as
mean (standard deviation) for continuous variables and as
a percentile for discrete variables. Prevalence rates of HPVTable 1 Demographic characteristics of 72 incarcerated H
counterparts
No. of cases
Demographics
Mean age, years (SD)
Education years
 9, n (%)
> 9, n (%)
Marital status
Married, n (%)
Single, separated, divorced, n (%)
Median duration of incarceration, days (25the75th percentile)
Recidivism, n (%)
Sexual behavior
Mean age at first sexual encounter, years (SD)
Median lifetime sexual partners (range)
Monogamous, lifetime, n (%)
Ever been a sex worker, n (%)
Ever had sexually transmitted disease, n (%)
Practicing anal sex, n (%)
Never/rarely use condoms with primary sexual partner, n (%)
Never/rarely use condoms with casual sexual partners, n (%)
Substance-taking behavior
Smoking history, n (%)
Using illicit drugs, n (%)
Mean age of starting drugs, years (SD)
Mean no. of drugs used, n (SD)
Mean age of starting injections, years (SD)
HIVZ human immunodeficiency virus; SDZ standard deviation.in each group were calculated. In univariate analysis, odds
ratios comparing cases and controls were calculated using
the Fisher exact test for 2  2 comparisons. The Chi-square
test was used for 2  3 or more comparisons when appro-
priate. Those variables with p< 0.1 were included in the
following multiple regression. A multiple logistic regression
analysis with best subsets selection using SAS 9.1 software
(SAS Institute Inc., Cary, NC, USA) was applied for the
association between significant variables and HPV infec-
tions. A p value < 0.05 was considered statistically
significant.Results
Of the 148 female inmates (mean age [standard deviation,
SD], 33.4 [5.1] years) who were successfully enrolled, 72
were HIV-positive and 76 were HIV-negative. Of the HIV-
positive women, four patients with either physiologic or
social reasons did not join the study. All of the enrolled
women were illicit drug users (included noninjection-type
drugs, such as amphetamine, ketamine, marijuana, fluni-
trazepam, etc., or the injection type of heroin). As shown
in Table 1, more than 70% of the HIV-positive cases had  9
years of education and more than 70% of them were single
or divorced. Most of the HIV-positive patients (95.8%) were
recidivists. For HIV-positive women, the mean age (SD) at
their first sexual encounter was 16.31 (2.03) years, and theIV-positive female illicit drug users and 76 HIV-negative
HIV-positive HIV-negative p value
72 76
32.7 (6.7) 34.2 (2.8) > 0.1
53 (73.6%) 37 (48.9%) 0.004
19 (26.4%) 38 (50.0%)
17 (23.6%) 28 (36.8%) 0.08
55 (76.4%) 48 (63.2%)
244 (150e570) 315 (120e600) > 0.1
69 (95.8%) 53 (69.7%) 0.104
16.23 (2.14) 17.59 (3.13) > 0.1
3 (1enumerous) 4 (1enumerous) > 0.1
12 (16.7%) 14 (18.4%) > 0.1
11 (15.3%) 9 (11.8%) > 0.1
19 (26.4%) 29 (38.2%) > 0.1
7 (9.7%) 11 (14.5%) > 0.1
45 (62.5%) 51 (67.1%) > 0.1
44 (61.1%) 30 (39.5%) 0.013
66 (91.7%) 66 (86.8%) > 0.1
72 (100%) 76 (100%) d
19.52 (5.89) 19.2 (5.03) > 0.1
2.83 (1.54) 2.74 (2.37) > 0.1
23.84 (5.55) 24.35 (5.04) > 0.1
Table 2 Prevalence of HPV in 72 incarcerated HIV-positive female illicit drug users and their 76 HIV-negative counterparts
HIV-positive HIV-negative p value
No. of cases 72 76
Cases with any HPV, n (%) 46 (63.9%) 36 (47.4%) 0.043
Cases with any oncogenic HPV, n (%) 30 (41.6%) 22 (28.9%) 0.10
Mean types of HPV infection in HPV-positive cases 2.41 1.53 0.014
HIVZ human immunodeficiency virus; HPVZ human papillomavirus.
HPV in Taiwanese HIV-positive women 285median number of lifetime sexual partners was three. Of
these women, 15.3% had been sex workers at some time in
their lives. More than 60% of the HIV-positive patients never
or rarely used a condom during sexual intercourse.
Compared with their counterparts, more of the HIV-positive
individuals had fewer educational years and never or rarely
used a condom (p< 0.05).
HPV infection was detected in 55.4% (82 of 148) of the
study patients, 63.9% (46 of 72) of HIV-positive women, and
47.4% (36 of 76) of the HIV-negative ones (pZ 0.043).
Oncogenic types of HPV were identified in 41.6% (30 of 72)
of HIV-positive women and in 28.9% (22 of 76) of HIV-
negative ones (pZ 0.10). In total, 166 episodes of HPV
infections were detected, 43.4% (72 of 166) of which were
oncogenic. A mean of 2.41 (111 of 46) types of HPV were
detected in HIV-positive women and 1.53 (55 of 36) types
were detected in their HIV-negative counterparts
(pZ 0.014) (Table 2). HPV 52, 51, and 58 were the most
commonly encountered oncogenic types, whereas HPV 62,
81, 84, and 72 were the most commonly encountered
nononcogenic types. Vaccine-preventable types (6, 11, 16,
18) were 5.4% (Fig. 1). Only 10.2% (10.9% of HIV-positive
patients) of the patients had been infected with vaccine-
preventable types.
A total of nine HIV-positive women (12.5%) and seven
HIV-negative ones (9.5%) had abnormal cervical cytology.
Patients with abnormal cytology (81.25%) tended to haveFigure 1. Genotypic distribution of 166 times of detection of hu
(HIV)-positive incarcerated female illicit drug users and 36 HIV-nega
58, 59, and 68 are considered oncogenic [dark bar]).oncogenic types of HPV infection. Atypical squamous cells
of unknown significance were found in four case group
individuals (5.5%) and three control patients (4.1%). Low-
grade squamous intraepithelial lesion was found in four
case group individuals (5.5%) and two control patients
(2.7%). Atypical squamous cells cannot exclude high-grade
squamous intraepithelial lesion, which were found in one
HIV-positive individual (1.39%) and two HIV-negative
women (2.8%). Trichomoniasis (9.5%), bacterial vaginosis
(6.8%), and candidiasis (3.4%) were the frequently
encountered infections.
HIV-positive patients with < 350 CD4þ T cells/mL did not
have a higher rate of any type (13 of 22, 59%) or oncogenic
type (8 of 22, 36.4%) of HPV infection in comparison with
patients with > 350 CD4þ T cells/mL (31 of 48, 64.6% for any
HPV and 21 of 48, 43.8% for oncogenic HPV, both p> 0.05).
Multiple logistic regression analysis revealed that HIV
serostatus was the only significant factor (odds
ratioZ 2.583, 95% confidence interval 1.071 e 6.231,
pZ 0.0347) associated with oncogenic HPV infection
(Table 3).Discussion
Although high prevalence rates of HPV in women infected
with HIV have been observed in many Western and Africanman papillomavirus among 46 human immunodeficiency virus
tive counterparts. (Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
Table 3 Multivariate logistic regression analysis for the prediction of any type of HPV infection and oncogenic HPV infection
among female illicit drug users
Any HPV Oncogenic HPV
Odds ratio 95% CI (range) Odds ratio 95% CI (range)
HIV status 1.963 0.886, 4.345 2.583* 1.071, 6.231
Age 0.567 0.285, 1.127 0.853 0.433, 1.080
Education 1.669 0.768, 3.629 1.985 0.856, 4.601
Marriage 1.344 0.599, 3.012 0.894 0.383, 2.087
Recidivism 0.976 0.347, 2.748 0.471 0.154, 1.437
Never/rarely use condoms with casual partners 1.072 0.509, 2.255 0.770 0.354, 1.676
CIZ confidence interval; HIVZ human immunodeficiency virus; HPVZ human papillomavirus.
*pZ 0.0347.
286 F.-Y. Chu et al.countries, few studies have focused on women in the
Western Pacific Rim.2e4 In studies in Korea, low rates
(10.4%) of HPV infection were observed for both women and
men in the general population, but the living situations of
people infected with HIV were largely unknown.16 In
Taiwan, according to a study done before the HIV epidemics
related to injection drug usage, 48.4% (15/31) of 31 HIV-
positive women were infected with HPV.12 Until now, the
status of HPV infection in HIV-positive female drug users
was unknown.
This study demonstrated that HIV serostatus was the
most important attributor to oncogenic HPV infection in
female illicit drug users. Many studies have also reported
high rates of persistence of detectable oncogenic HPV DNA
in women who were infected with HIV.5,6 The study findings
indicated that HIV-related immunocompromised status
would contribute to the persistence of HPV infection.
However, the mechanisms by which immunosuppression
contributes to the increased risks of HPV-related diseases is
not well understood. CD4þ T-cell levels were used as
a marker of immunosuppression, but the markers for HPV-
specific immunity were not known.17
In Taiwan, the general prevalence of HPV alone and
oncogenic HPV infection in adult women is 19.85%18 and
11.1%,19 respectively. In this study, higher rates of HPV
infections were observed in incarcerated HIV-negative
women (47.4%) in comparison with the general population
(19.85%).18 Therefore, the characteristics of illicit drug
users, including low number of years of education, unstable
marital status, low rate of condom usage, and high numbers
of sexual partners, were considered risk factors for HPV
infection among female drug users.11
The median duration of incarceration for these women
inmates was approximately 1 year in both groups in this
study, so the detected HPV infections implicated possible
persistent infections. Previous studies had demonstrated
HPV infections would not abate for a median of 8
months1,20,21; thus, this point prevalence rate would
approximate the rate of persistent infection, considered to
be the major risk factor in the development of precan-
cerous and cancer lesions.6,17
HPV types 52, 51, and 58 were the most commonly
encountered oncogenic types in this study. Research has
also demonstrated that HPV types 52 and 58 were the most
prevalent oncogenic types in Taiwan.19 Distribution of
different HPV types may vary across areas. For example, inthe United States, HPV types 53, 52, and 59 were the most
commonly encountered oncogenic HPV genotypes.22 HPV
type 16 was the most commonly detected type in Brazil,
type 52 in Uganda, and type 33 in Zimbabwe.3,4,23 HPV
types included in available HPV vaccines (types 6, 11, 16,
and 18) comprised only 5.4% of the total infections in this
study; therefore, these HPV vaccines may not provide
enough protection for female drug users in Taiwan.
Previous studies had confirmed that immunosuppression
may accelerate the progression of HPV-associated
precursor lesions,2,17 and HIV-positive patients with CD4þ
T-cell counts less than 100 cells/mL were reported to have
a twofold relative risk of developing cervical cancer.24
However, because the patients in this study were young
and not in a severe immunosuppressive status, and the
number of cases was small, an association between cervical
dysplasia and CD4þ cell counts could not be established.
There are several limitations of this study. First, this
study focused on the incarcerated female population, and
hence, no generalizations could be made. Second, this
cross-sectional study did not reveal the outcome of HPV
infection, for which longitudinal follow-up would be
necessary. Third, the general women population was not
enrolled in this study. However, the prevalence of HPV
infection in the general population and patient demo-
graphics has already been reported in previous large-scale
studies in Taiwan18,19; the value of this study could not be
neglected despite the limitations.
This study demonstrated that HPV infections are
common in female illicit drug users. Women infected with
HIV were found to be more susceptible to HPV and onco-
genic HPV infections in comparison with those without HIV
infections. This study revealed that the burden of HPV
infection among female illicit drug users is high. Thus,
aggressive screening and early detection for cervical
dysplasia are highly recommended.Acknowledgments
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